lobbying_activities: 3150969

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
3150969	6e1300ad-2a82-474f-b9cd-4065f8ef7558	Q1	AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS	3457	AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS	2024	first_quarter	PHA	Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. The PROTECT 340B Act (H.R. 2534) and the 340B Pharmaceutical Access to Invest in Essential, Needed Treatments & Support Act of 2024 (H.R. 7635), provisions related to enforcement of the 340B Drug Pricing Program. Issues related to pharmacy residency funding (generally, no specific legislation). Issues related to drug price negotiations and patient out-of-pocket costs (generally, no specific legislation). Issues related to authorization of technician product verification (generally, no specific legislation). The Biosimilar Red Tape Elimination Act (S. 2305), issues related to accelerating biosimilar adoption.	Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE		240000	0	0	2024-04-18T12:11:57-04:00